Biomarker ID | 532 |
PMID | 20473923 |
Year | 2010 |
Biomarker | KLK15 (kallikrein-related peptidase) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | High levels associated with shorter progression-free survival. |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 2.229 (95% CI: 1.353–3.673); Multivariate: HR: 1.802 (95% CI:1.037–3.132); Step Wise Selection: HR: 1.819 (95% CI: 1.053-3.141) |
Effect on Pathways | Pathways Include:-Intrinsic Prothrombin Activation Pathway,MSP-RON Signaling, PPAR Alpha Pathway,Blood Coagulation Cascade |
Experiment | PSA recurrence Vs No PSA recurrence |
Type of Biomarker | Prognostic |
Cohort | For immunohistochemical expression of KLK15, 193 patients were included out of which 63 had PSA defined recurrence and 130 did not have PSA defined recurrence, with Avg time= 27 months. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | Univariate: p = 0.002; Multivariate: p=0.037; StepWise Inclusion: p=0.032 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | Forward and backward stepwise elimination procedures including all six variables (Age, PSA, Tumor Stage, Tumor Grade, Surgical Margin, KLK15) |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Dataset |
Technical Name | KLK15 |